Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients

Gaojie Liu, Jie Zhu, Menglei Yu, Canfeng Cai, Yu Zhou, Min Yu, Zhiqiang Fu, Yuanfeng Gong, Bin Yang, Yingru Li, Quanbo Zhou, Qin Lin, Huilin Ye, Liangtao Ye, Xiaohui Zhao, Zhihua Li, Rufu Chen, Fanghai Han, Chaoming Tang, Bing ZengJournal of Translational Medicine 2015 · DOI

Abstract

These results indicate that GDH plays a critical role in CRC progression, and may provide a novel metabolism therapeutic target for CRC treatment.

Introduction

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, with the majority of deaths attributed to distant metastasis, particularly to the liver. A hallmark of cancer progression is metabolic reprogramming, often referred to as the Warburg effect, where cancer cells alter their metabolic pathways to support rapid proliferation and invasion.

Glutaminolysis, the process by which cells break down the amino acid glutamine for energy and biosynthetic precursors, has emerged as a critical metabolic pathway in various malignancies. Glutamate Dehydrogenase (GDH) is the enzyme responsible for the final step of this pathway. While GDH's role has been explored in other cancers, its clinical significance and mechanistic contribution to CRC progression have remained largely uncharacterized. This study investigates GDH as a potential prognostic marker and a driver of metastasis in CRC.

Methods and Materials

The researchers employed a comprehensive approach integrating clinical validation with functional molecular assays:

  • Clinical Cohort: The study analyzed GDH expression in a cohort from Sun Yat-sen Memorial Hospital, including 20 fresh-frozen CRC and adjacent non-tumor tissue pairs, and 104 paraffin-embedded archival specimens (collected 2002–2005) with a median follow-up of 62.5 months.
  • Molecular Analysis: GDH levels were quantified using qPCR, Western blotting, and Immunohistochemistry (IHC).
  • Functional Assays: To determine the biological role of GDH, shRNA-mediated knockdown was performed in CRC cell lines (SW480 and LoVo). Effects on cell proliferation, migration, and invasion were assessed via MTT, wound healing, and transwell assays.
  • Pathway Mapping: The relationship between GDH and the STAT3 signaling pathway was explored using the inhibitor AG490 to observe impacts on Epithelial-Mesenchymal Transition (EMT) markers.

Results

GDH Upregulation in Colorectal Cancer

Initial findings confirmed that GDH is significantly overexpressed in CRC tissues compared to normal colonic mucosa. This upregulation was consistent across various human CRC cell lines compared to the normal colon epithelial line NCM460.

GDH expression levels are significantly elevated in CRC cell lines and tumor tissues (T) compared to normal controls (N).

Clinical and Prognostic Significance

High GDH expression was strongly associated with aggressive clinical features, including larger tumor size, advanced TNM stage, and the presence of lymph node and liver metastasis.

Crucially, GDH levels served as a powerful predictor of patient outcomes. Patients with high GDH expression exhibited a 5-year overall survival (OS) rate of 38.1%, significantly lower than the 65.1% observed in the low-expression group. Multivariate analysis identified high GDH expression as an independent risk factor for both death and disease recurrence.

Kaplan-Meier curves demonstrate that high GDH expression is associated with significantly reduced overall survival and disease-free survival in CRC patients.

Mechanistic Role in Metastasis

The study revealed that GDH acts as more than just a metabolic enzyme; it functions as a signaling trigger. High GDH levels correlate with the activation of the STAT3 pathway, which in turn promotes the Epithelial-Mesenchymal Transition (EMT). By upregulating mesenchymal markers like Vimentin and ZEB1 and suppressing the epithelial marker E-cadherin, GDH facilitates the migration and invasion of CRC cells, providing a mechanistic link to liver metastasis.

Discussion

This research identifies GDH as a novel and independent prognostic marker for CRC. The discovery that GDH drives metastasis through STAT3-mediated EMT suggests that metabolic enzymes can serve as critical switches for oncogenic signaling pathways.

While these results are compelling, the study is limited by its relatively small, single-center cohort. Future work should focus on validating these findings in larger, multi-center studies and investigating the precise triggers—such as genetic mutations or microenvironmental factors—that lead to GDH overexpression. Ultimately, GDH represents a potential therapeutic target, though developing selective inhibitors that do not interfere with normal metabolism remains a significant challenge.

Summary updated

Abstract

These results indicate that GDH plays a critical role in CRC progression, and may provide a novel metabolism therapeutic target for CRC treatment.
BibTeX
@article{liu2015glutamate,
  author = {Gaojie Liu and Jie Zhu and Menglei Yu and Canfeng Cai and Yu Zhou and Min Yu and Zhiqiang Fu and Yuanfeng Gong and Bin Yang and Yingru Li and Quanbo Zhou and Qin Lin and Huilin Ye and Liangtao Ye and Xiaohui Zhao and Zhihua Li and Rufu Chen and Fanghai Han and Chaoming Tang and Bing Zeng},
  title = {{Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients}},
  journal = {Journal of Translational Medicine},
  year = {2015},
  doi = {10.1186/s12967-015-0500-6},
}
Figure